menu
    • menu
    [{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"WallachBeth Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Tafenoquine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ WallachBeth Capital","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ WallachBeth Capital"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Tafenoquine

    Menu

    Tafenoquine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Trial Protocol

                            Details : Arakoda (tafenoquine) is the inhibitor of hematin polymerization which is being evaluated in phase 2 clinical trials for the treatment of babesiosis patients.

                            Brand Name : Arakoda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 02, 2024

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            60 Degrees Receives FDA Intent to Respond to Tafenoquine-Babesiosis Protocol in April 2024

                            Details : Arakoda (tafenoquine) is the inhibitor of hematin polymerization which is being evaluated in phase 2 clinical trials for the treatment of babesiosis patients.

                            Brand Name : Arakoda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 14, 2024

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine After Jan 17 FDA Meeting

                            Details : Arakoda (tafenoquine) is the inhibitor of hematin polymerization which is being evaluated in phase 2 clinical trials for the treatment of babesiosis patients.

                            Brand Name : Arakoda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 22, 2024

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emergin...

                            Details : Arakoda (tafenoquine) is an oral hematin polymerization inhibitor, small mlecule drug which is being evaluated in preclinical studies for the treatment of hospitalized babesiosis.

                            Brand Name : Arakoda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 26, 2023

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an E...

                            Details : Arakoda (tafenoquine) oral tablet is being developing the tafenoquine regimen of ARAKODA® for a potential indication in treating hospitalized babesiosis patients. The meeting will take place on January 15, 2024.

                            Brand Name : Arakoda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 15, 2023

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commerci...

                            Details : Arakoda (tafenoquine) oral tablet is being investigated in Phase IIB Study for COVID-19 patients with mild-moderate symptoms and low risk of disease and is approved by FDA for the treatment of prophylaxis of malaria in patients aged 18 years of age and o...

                            Brand Name : Arakoda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2023

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            60 Degrees Pharma Withdraws COVID Phase IIB IND, will Resubmit Pending Assessment of Ability to Meet FDA Requi...

                            Details : Arakoda (tafenoquine) oral tablet is being investigated in Phase IIB Study for COVID-19 patients with mild-moderate symptoms and low risk of disease and is approved by FDA for the treatment of prophylaxis of malaria in patients aged 18 years of age and o...

                            Brand Name : Arakoda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 18, 2023

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ...

                            Details : Arakoda (tafenoquine) oral tablet is being investigated in Phase IIB Study for COVID-19 patients with mild-moderate symptoms and low risk of disease and is approved by FDA for the treatment of prophylaxis of malaria in patients aged 18 years of age and o...

                            Brand Name : Arakoda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 15, 2023

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-N...

                            Details : ARAKODA (tafenoquine) an oral tablet, is an anti-malarial indicated in the U.S. for the prophylaxis of malaria in individuals aged 18 years and older.

                            Brand Name : Arakoda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 31, 2023

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            60 Degrees Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : WallachBeth Capital

                            Deal Size : $7.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering

                            Details : The net proceeds will be used to fund the development of new indications for comapny's products with a focus on executing a COVID-19 clinical trial involving Arakoda (tafenoquine) which is active against SARS-CoV-2 at clinically relevant concentrations.

                            Brand Name : Arakoda

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 14, 2023

                            Lead Product(s) : Tafenoquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : WallachBeth Capital

                            Deal Size : $7.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth